A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With an Exploratory Arm in Patients With Newly Diagnosed High-Risk AML

Next Previous
Trial Profile

A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With an Exploratory Arm in Patients With Newly Diagnosed High-Risk AML

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Alvocidib (Primary) ; Cytarabine; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Sponsors Tolero Pharmaceuticals

    • Most Recent Events

    • 14 Jan 2018 Planned number of patients changed from 99 to 119.
    • 21 Jun 2017 According to Tolero Pharmaceuticals media release, the company is adding European study centers to this trial.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top